J&J’s talc trouble continues: Johnson & Johnson ordered to pay $40 million in baby powder cancer case

A California jury ordered Johnson & Johnson to pay $40 million to two women who say decades of using its talc-based baby powder caused their ovarian cancer; the company said it will immediately appeal and continues to deny its products cause cancer or contain asbestos. J&J has faced more than 67,000 talc-related lawsuits, halted US sales of talc powder in 2020 and seen three federal courts reject its attempts to resolve the litigation via bankruptcy, with these two cases the first to go to trial since that dismissal. The firm’s mixed trial history—verdicts as high as $4.69 billion, some wins and reductions on appeal, and recent large mesothelioma awards (including a >$900 million verdict)—keeps substantial legal and financial exposure and settlement uncertainty on the table for investors.

Analysis

A California jury ordered Johnson & Johnson to pay $40 million to two women who say decades of using its talc-based baby powder caused their ovarian cancer; the plaintiffs were diagnosed in 2014 and 2018 and testified to major surgeries and multiple rounds of chemotherapy. Johnson & Johnson says its products are safe, do not contain asbestos and will immediately appeal, and the company stopped selling talc-based baby powder in the US in 2020 after switching to a cornstarch product.

The case sits against a backdrop of more than 67,000 talc-related lawsuits and three federal rejections of J&J's bankruptcy strategy to resolve the litigation, making these two trials the first to proceed since that Chapter 11 attempt was dismissed. J&J's trial history is mixed, with verdicts ranging from defense wins to awards as high as $4.69 billion and recent mesothelioma verdicts including one exceeding $900 million, which keeps sizable potential liability on the table.

This verdict preserves material legal and reputational risk for JNJ, implying continued share-price sensitivity to trial outcomes and appellate developments rather than near-term operational performance. Appellate reversals, verdict reductions, settlement activity, or further large adverse awards will be the primary catalysts for changes in the company's contingent liabilities and investor returns.

Key Decisions for Investors

• Re-evaluate exposure to JNJ given persistent litigation risk and recent adverse verdicts; consider trimming positions or purchasing downside protection with options until the appellate pathway is clearer
• Monitor legal milestones closely — appeals, federal court rulings on bankruptcy strategy, trial schedules and any announced settlement negotiations — as these will materially change contingent liability estimates
• Prioritize upcoming company filings for updates on litigation reserves and cash flow impact and avoid adding material new exposure until there is evidence of a stable resolution framework or sustained appellate defense success